Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹18 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹-2 Cr
ROE
-6.5 %
ROCE
-1.8 %
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
32.35
EV/EBITDA
-45.6
Div. Yield
0 %
Debt to Equity
1.4
Book Value
₹1.2
EPS
₹-0.3
Face value
10
Shares outstanding
75,770,000
CFO
₹5.58 Cr
EBITDA
₹-10.65 Cr
Net Profit
₹-95.77 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Transgene Biotek
| -23.8 | -8.4 | -18.6 | -35.8 | -1.0 | -6.5 | 2.4 |
|
BSE Healthcare
| -3.7 | -3.4 | -3.7 | 3.4 | 24.8 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Transgene Biotek
| -48.8 | -29.4 | 234.6 | -33.7 | -7.0 | 113.1 | -31.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Transgene Biotek
|
2.4 | 18.2 | 0.2 | -1.9 | -416.2 | -19.8 | -- | 2.1 |
| 253.0 | 138.7 | 34.5 | -3.4 | -5.4 | -48.6 | -- | 10.1 | |
| 1,610.3 | 26,813.3 | 6,112.8 | 847.2 | 17.2 | 9.2 | 31.7 | 2.7 | |
| 173.7 | 954.4 | 264.6 | 19.3 | 8.9 | 6.2 | 41.2 | 4.1 | |
| 833.4 | 10,137.4 | 6,537.7 | 207.0 | 4.6 | 11.5 | 49 | 5.3 | |
| 243.9 | 234.2 | 143.3 | 10.6 | 3.5 | 5.4 | 22 | 1.3 | |
| 1,243.7 | 12,739.9 | 1,781.6 | 341.3 | 19.8 | 12.4 | 36.6 | 4.3 | |
| 397.0 | 485.5 | 71.3 | 19.8 | 31.4 | 17.9 | 24.5 | 4.0 | |
| 184.9 | 992.8 | 414.3 | 20.3 | 8.0 | 3.4 | 48.8 | 1.6 | |
| 473.4 | 521.4 | 18.6 | 25.3 | -9.9 | -10.2 | -- | 0.6 |
No Review & Analysis are available.
Transgene Biotek Limited engages in the provision of research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics. The company offers TrabiDHA for use in health foods, baby food/formulas,... health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India. Read more
Incorporated
1990
Chairman
K Koteswara Rao
Managing Director
K Koteswara Rao
Headquarters
Sangareddy, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Transgene Biotek Ltd is ₹2.40 (BSE) as of 19-Mar-2026 14:01 IST. Transgene Biotek Ltd has given a return of -0.95% in the last 3 years.
Since, TTM earnings of Transgene Biotek Ltd is negative, P/E ratio is not available.
The P/B ratio of Transgene Biotek Ltd is 2.06 times as on 19-Mar-2026, a 26 discount to its peers’ median range of 2.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
2.53
|
|
2024
|
0.00
|
5.76
|
|
2023
|
0.00
|
1.66
|
|
2022
|
0.00
|
1.57
|
|
2021
|
0.00
|
1.56
|
The 52-week high and low of Transgene Biotek Ltd are Rs 5.26 and Rs 1.83 as of 19-Mar-2026.
Transgene Biotek Ltd has a market capitalisation of ₹ 18 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Transgene Biotek Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.20
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.